China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

Why is China Resources Boya Bio-pharmaceutical Group Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 11.74%

The company has been able to generate a Return on Capital Employed (avg) of 11.74% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -6.79% and Operating profit at -14.39% over the last 5 years

Flat results in Sep 25

INTEREST(HY) At CNY 0.57 MM has Grown at 435.3%
OPERATING CASH FLOW(Y) Lowest at CNY 141.51 MM
RAW MATERIAL COST(Y) Grown by 7.08% (YoY)

With ROE of 3.29%, it has a fair valuation with a 1.62 Price to Book Value

Over the past year, while the stock has generated a return of -32.89%, its profits have risen by 43.7% ; the PEG ratio of the company is 1.1
At the current price, the company has a high dividend yield of 1.9

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -32.89% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to China Resources Boya Bio-pharmaceutical Group Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is China Resources Boya Bio-pharmaceutical Group Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

-32.05%

-2.20

19.55%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.79%

EBIT Growth (5y)

-14.39%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.41

Sales to Capital Employed (avg)

0.28

Tax Ratio

17.37%

Dividend Payout Ratio

40.65%

Pledged Shares

Institutional Holding

ROCE (avg)

11.74%

ROE (avg)

4.93%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.62

EV to EBIT

39.40

EV to EBITDA

24.23

EV to Capital Employed

2.02

EV to Sales

5.14

PEG Ratio

1.13

Dividend Yield

1.92%

ROCE (Latest)

5.12%

ROE (Latest)

3.29%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET SALES(9M)

At CNY 1,473.92 MM has Grown at 18.76%

NET PROFIT(Q)

At CNY 106.25 MM has Grown at 69.14%

-14What is not working for the Company

INTEREST(HY)

At CNY 0.57 MM has Grown at 435.3%

OPERATING CASH FLOW(Y)

Lowest at CNY 141.51 MM

RAW MATERIAL COST(Y)

Grown by 7.08% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -37.17 %

Here's what is working for China Resources Boya Bio-pharmaceutical Group Co., Ltd.

Net Sales

At CNY 1,473.92 MM has Grown at 18.76%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Profit

At CNY 106.25 MM has Grown at 69.14%

over average net sales of the previous four periods of CNY 62.82 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Here's what is not working for China Resources Boya Bio-pharmaceutical Group Co., Ltd.

Interest

At CNY 0.57 MM has Grown at 435.3%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Cash Flow

Lowest at CNY 141.51 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debt-Equity Ratio

Highest at -37.17 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 7.08% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Non Operating Income

Highest at CNY 0.36 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income